Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prasterone for HSDD in postmenopausal women
NCT03619005Phase 3Withdrawn
- Sponsor
- Endoceutics
- Start
- Nov 2018
- Primary completion
- Aug 2019
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 3 trial of prasterone in hypoactive sexual desire disorder (HSDD), sponsored by Endoceutics. Planned start Nov 2018; status: withdrawn.
02
Drugs
prasterone
03
Conditions
hypoactive sexual desire disorder (HSDD)
Beyond the preview
Go deeper on NCT03619005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03619005.